AR074483A1 - Composiciones, metodos y usos para inducir al crecimiento viral - Google Patents

Composiciones, metodos y usos para inducir al crecimiento viral

Info

Publication number
AR074483A1
AR074483A1 ARP090104712A ARP090104712A AR074483A1 AR 074483 A1 AR074483 A1 AR 074483A1 AR P090104712 A ARP090104712 A AR P090104712A AR P090104712 A ARP090104712 A AR P090104712A AR 074483 A1 AR074483 A1 AR 074483A1
Authority
AR
Argentina
Prior art keywords
compositions
methods
induce
growth
viral growth
Prior art date
Application number
ARP090104712A
Other languages
English (en)
Inventor
O'neil Wiggan
Jill A Livengood
Dan T Stinchcomb
Jorge Osorio
Original Assignee
Inviragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inviragen Inc filed Critical Inviragen Inc
Publication of AR074483A1 publication Critical patent/AR074483A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

Las formas de realización de la presente informan acerca de métodos, composiciones y usos para inducir y/o acelerar el crecimiento de virus. En ciertas formas de realización, los métodos, composiciones y usos por lo general se relacionan con composiciones de copolímeros para inducir el crecimiento de virus, reducir el tiempo de retraso y/o incrementar el tamano de placa viral. En otras formas de realización, los métodos, composiciones y usos de composiciones de copolímeros pueden ser para inducir el crecimiento de flavivirus, reducir su retraso de crecimiento y/o incrementar su tamano de placa.
ARP090104712A 2008-12-05 2009-12-04 Composiciones, metodos y usos para inducir al crecimiento viral AR074483A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12026208P 2008-12-05 2008-12-05

Publications (1)

Publication Number Publication Date
AR074483A1 true AR074483A1 (es) 2011-01-19

Family

ID=42231513

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104712A AR074483A1 (es) 2008-12-05 2009-12-04 Composiciones, metodos y usos para inducir al crecimiento viral

Country Status (20)

Country Link
US (3) US8871487B2 (es)
EP (1) EP2366024B1 (es)
JP (2) JP5728742B2 (es)
KR (1) KR101784951B1 (es)
CN (2) CN105219734B (es)
AR (1) AR074483A1 (es)
AU (1) AU2009322175B2 (es)
BR (2) BR122020015754B8 (es)
CA (1) CA2745962C (es)
CO (1) CO6390063A2 (es)
CU (1) CU20110128A7 (es)
HR (1) HRP20191324T1 (es)
IL (2) IL213389B (es)
MX (2) MX2011005886A (es)
MY (1) MY178195A (es)
NZ (1) NZ593415A (es)
SG (3) SG10202007719TA (es)
TW (2) TWI573874B (es)
WO (1) WO2010065911A1 (es)
ZA (2) ZA201104364B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202007719TA (en) * 2008-12-05 2020-09-29 Takeda Vaccines Inc Compositions, methods and uses for inducing viral growth
EP2746386A1 (en) * 2012-12-21 2014-06-25 Lonza Cologne GmbH Materials and methods for cell culture
CA2981277A1 (en) * 2015-03-30 2016-10-06 Ajinomoto Co., Inc. Human serum albumin-containing culture medium for growth of neural stem cells
WO2023147337A2 (en) * 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2024118740A1 (en) * 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
AU4330597A (en) 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US6869793B2 (en) * 1996-09-24 2005-03-22 Bavarian Nordic Research Institute Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
BR0014818A (pt) 1999-10-08 2002-06-18 Gruenenthal Gmbh Imidazo-3-il-aminas bicìclicas procedimento de preparação e medicamentos que contém como substância ativa pelo menos uma imidazo-3-il-amina bicìclica
AU3844101A (en) * 2000-02-16 2001-08-27 Us Health Avirulent, immunogenic flavivirus chimeras
US20030180329A1 (en) * 2002-01-15 2003-09-25 Monath Thomas P. Viral vaccine production method
CA2478932A1 (en) * 2002-03-29 2003-10-16 Merck & Co., Inc. Large scale methods of producing adenovirus and adenovirus seed stocks
RU2237065C2 (ru) 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
PL199642B1 (pl) * 2002-11-15 2008-10-31 Inst Immunologii I Terapii Do Preparat bakteriofagowy o podwyższonej trwałości oraz zastosowanie blokowego kopolimeru tlenku etylenu i tlenku propylenu
JP2010506166A (ja) * 2006-10-05 2010-02-25 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ デング熱の診断及び治療
HUE031617T2 (en) * 2007-04-06 2017-07-28 Takeda Vaccines Inc Methods and preparations for live attenuated viruses
CA2639954C (en) * 2008-02-11 2017-08-15 Aaron R. Wheeler Droplet-based cell culture and cell assays using digital microfluidics
SG10202007719TA (en) 2008-12-05 2020-09-29 Takeda Vaccines Inc Compositions, methods and uses for inducing viral growth

Also Published As

Publication number Publication date
BR122020015754B1 (pt) 2021-03-23
CO6390063A2 (es) 2012-02-29
NZ593415A (en) 2014-04-30
US8871487B2 (en) 2014-10-28
KR20110127117A (ko) 2011-11-24
BRPI0922788B1 (pt) 2021-03-23
CN102272294A (zh) 2011-12-07
US20100144015A1 (en) 2010-06-10
IL213389B (en) 2018-10-31
EP2366024A1 (en) 2011-09-21
US20180251737A1 (en) 2018-09-06
SG10201503671TA (en) 2015-06-29
BRPI0922788B8 (pt) 2021-05-25
EP2366024A4 (en) 2012-07-04
CN102272294B (zh) 2015-09-02
BRPI0922788A2 (pt) 2015-08-18
JP2015109874A (ja) 2015-06-18
WO2010065911A1 (en) 2010-06-10
BRPI0922788A8 (pt) 2017-12-12
ZA201104364B (en) 2022-10-26
IL238819A (en) 2017-08-31
TW201030148A (en) 2010-08-16
MX353602B (es) 2018-01-19
AU2009322175B2 (en) 2014-10-09
JP5728742B2 (ja) 2015-06-03
US9890362B2 (en) 2018-02-13
CA2745962A1 (en) 2010-06-10
US20150010983A1 (en) 2015-01-08
KR101784951B1 (ko) 2017-10-12
CN105219734A (zh) 2016-01-06
TW201514302A (zh) 2015-04-16
TWI461536B (zh) 2014-11-21
CA2745962C (en) 2018-11-27
IL213389A0 (en) 2011-07-31
IL238819A0 (en) 2015-06-30
SG171972A1 (en) 2011-07-28
TWI573874B (zh) 2017-03-11
SG10202007719TA (en) 2020-09-29
JP2012510822A (ja) 2012-05-17
MX2011005886A (es) 2011-07-28
HRP20191324T1 (hr) 2019-10-18
ZA201600550B (en) 2021-08-25
EP2366024B1 (en) 2019-05-01
JP6174066B2 (ja) 2017-08-02
AU2009322175A1 (en) 2011-06-30
CN105219734B (zh) 2020-03-03
MY178195A (en) 2020-10-06
CU20110128A7 (es) 2012-06-21
BR122020015754B8 (pt) 2021-04-06

Similar Documents

Publication Publication Date Title
UY35131A (es) Composiciones, métodos y usos de construcciones de virus del dengue de serotipo-4
ECSP17064986A (es) Compuestos antivirales
CR20110453A (es) Combinación de un inhibidor de nucléosido polimerasa con un inhibidor de proteasa macrocíclica y su uso en el tratamiento de hepatitis c, fibrosis hepática y función hepática alterada
UY35266A (es) Compuestos antivirales
CL2018000515A1 (es) Virus de la enfermedad de newcastle y usos de los mismos (divisional sol. 2532-2015)
ECSP14013315A (es) Inhibidores de aplicación viral
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
CL2012000573A1 (es) Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv.
CL2008000321A1 (es) Compuesto macrociclo en forma cristalina, inhibidor del virus de la hepatitis c (vhc); mezcla de una o mas formas cristalinas; procesos de preparacion de las formas cristalinas; y composicion farmaceutica que las comprende.
AR065984A1 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. composiciones farmaceuticas.
AR058215A1 (es) Metodos y proteinas para el tratamiento profilactico y o terapeutico de los cuatro serotipos del virus de dengue y otros flavivirus
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
ECSP10010002A (es) Derivados indólicos 2,3 sustituidos y métodos de uso de los mismos
BR112014006324B8 (pt) composição e seu uso para o tratamento de hcv
CO6541585A2 (es) Composiciones de lipopétidos y métodos relacionados
ECSP099447A (es) Derivados indólicos con anillo unido en las posiciones 4,5 y sus métodos de uso
CL2009002207A1 (es) Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
ECSP066794A (es) Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
AR074483A1 (es) Composiciones, metodos y usos para inducir al crecimiento viral
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
SV2011003796A (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
AR101814A1 (es) Partícula de tipo virus flavivirus
EA201290373A1 (ru) Синергическая противовирусная композиция и ее применение
NI201300045A (es) Inhibidores de apoptosis y usos de los mismos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FG Grant, registration